Nov 30, 2022 | Press Releases
UTMB will collaborate with HDT Bio Corp. and the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Labs to develop vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV) The 5-year $59M prototype project will develop...
Nov 7, 2022 | Press Releases
SEATTLE–HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today it has been selected to join Blue Knight, a collaboration between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research...
Nov 1, 2022 | Press Releases
SEATTLE, WA (November 1, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today CEO Steven Reed will give a corporate presentation on Nov. 8, 3 pm, Fourth Floor, (Adams) at the BioFuture Investor Conference at the...
Aug 23, 2022 | Press Releases
The company’s saRNA vaccine technology, using its proprietary LION™ delivery system, already has proved successful in development of COVID-19 vaccines SEATTLE, WA (August 23, 2022) – HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases,...
Aug 8, 2022 | Press Releases
The antiviral product, HDT-201, will utilize company’s RNA/LION™ platform technology and ultimately will be available to the public. SEATTLE, WA (August 8, 2022) – HDT Bio Corp., a developer of immunotherapies for infectious diseases and oncology, announced today it...
Jul 20, 2022 | Press Releases
SEATTLE, WA (July 20, 2022) – HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today it has been awarded a nearly $1.5M Phase 2 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and...
